Vabysmo vs Tyrvaya
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Vabysmo | US Tyrvaya | |
|---|---|---|
| Generic name | faricimab | varenicline nasal spray |
| Drug class | VEGF/Ang-2 Bispecific Inhibitor (Eye Injection) | Nicotinic Acetylcholine Receptor Agonist (Nasal) |
| Treats | Wet macular degeneration, diabetic macular edema | Dry eye disease |
| Category | Eye Health | Eye Health |
| Manufacturer | Genentech (Roche) | Viatris |
| Year approved | 2022 | 2021 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $85M | — |
| Common side effects | Eye inflammation, Floaters, Increased eye pressure, Blurred vision | Sneezing, Cough, Throat irritation, Nose irritation |
Frequently asked questions
Is Vabysmo or Tyrvaya better?
Neither is universally "better." Vabysmo (faricimab) and Tyrvaya (varenicline nasal spray) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Vabysmo and Tyrvaya?
Vabysmo is a VEGF/Ang-2 Bispecific Inhibitor (Eye Injection) made by Genentech (Roche), while Tyrvaya is a Nicotinic Acetylcholine Receptor Agonist (Nasal) made by Viatris. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Vabysmo has the larger estimated TV advertising budget of the two.